Dermata Therapeutics, Inc.
DRMA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.08 | 0.03 |
| FCF Yield | -5,404.48% | -3,610.46% | -130.31% | -26.19% |
| EV / EBITDA | 0.24 | -29.37 | 8.53 | -1.39 |
| Quality | ||||
| ROIC | -801.57% | -1.47% | -1.36% | -77.31% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.91 | 0.82 | 0.92 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -74.18% | 27.45% | -55.17% | -41.33% |
| Safety | ||||
| Net Debt / EBITDA | 0.26 | -30.09 | -98.93 | 1.37 |
| Interest Coverage | 0.00 | 0.00 | 152.17 | -172.25 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |